Precision Medicine in Type 1 Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2022 Aug 22

PMID 35994083

Authors

Alice L J Carr

Carmella Evans-Molina

Richard A Oram

Affiliations

Soon will be listed here.

Abstract

First envisioned by early diabetes clinicians, a person-centred approach to care was an aspirational goal that aimed to match insulin therapy to each individual's unique requirements. In the 100 years since the discovery of insulin, this goal has evolved to include personalised approaches to type 1 diabetes diagnosis, treatment, prevention and prediction. These advances have been facilitated by the recognition of type 1 diabetes as an autoimmune disease and by advances in our understanding of diabetes pathophysiology, genetics and natural history, which have occurred in parallel with advancements in insulin delivery, glucose monitoring and tools for self-management. In this review, we discuss how these personalised approaches have improved diabetes care and how improved understanding of pathogenesis and human biology might inform precision medicine in the future.

Citing Articles

Are Trends in Economic Modeling of Pediatric Diabetes Mellitus up to Date with the Clinical Practice Guidelines and the Latest Scientific Findings?.

Cardona-Hernandez R, De la Cuadra-Grande A, Monje J, Echave M, Oyaguez I, Alvarez M J Health Econ Outcomes Res. 2025; 12(1):30-50.

PMID: 39911635 PMC: 11797704. DOI: 10.36469/001c.127920.

Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art.

Laszczych D, Czernicka A, Laszczych K Pharmacol Rep. 2025; .

PMID: 39833509 DOI: 10.1007/s43440-025-00697-7.

Circulating T Cell Subsets in Type 1 Diabetes.

Ferreira-Hermosillo A, Santana-Sanchez P, Vaquero-Garcia R, Garcia-Saenz M, Castro-Rios A, Chavez-Rueda A Cells. 2025; 14(1.

PMID: 39791749 PMC: 11719944. DOI: 10.3390/cells14010048.

Machine Learning Algorithms Based on Time Series Pre-Clustering for Nocturnal Glucose Prediction in People with Type 1 Diabetes.

Kladov D, Berikov V, Semenova J, Klimontov V Diagnostics (Basel). 2024; 14(21).

PMID: 39518393 PMC: 11544917. DOI: 10.3390/diagnostics14212427.

Advances in Type 1 Diabetes Mellitus Management in Children.

Bahal M, Pande V, Dua J, Mane S Cureus. 2024; 16(8):e67377.

PMID: 39310514 PMC: 11416143. DOI: 10.7759/cureus.67377.

References

So M, Speake C, Steck A, Lundgren M, Colman P, Palmer J . Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. Endocr Rev. 2021; 42(5):584-604. DOI: 10.1210/endrev/bnab013. View

Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

Hovorka R, Allen J, Elleri D, Chassin L, Harris J, Xing D . Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010; 375(9716):743-51. DOI: 10.1016/S0140-6736(09)61998-X. View

. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2009; 33(1):17-22. PMC: 2797966. DOI: 10.2337/dc09-1502. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Patel K, Oram R, Flanagan S, De Franco E, Colclough K, Shepherd M . Type 1 Diabetes Genetic Risk Score: A Novel Tool to Discriminate Monogenic and Type 1 Diabetes. Diabetes. 2016; 65(7):2094-2099. PMC: 4920219. DOI: 10.2337/db15-1690. View

Tanenbaum M, Iturralde E, Hanes S, Suttiratana S, Ambrosino J, Ly T . Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. J Health Psychol. 2017; 25(4):429-438. PMC: 7162558. DOI: 10.1177/1359105317718615. View

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

10.

Elliott R, Crossley J, Berryman C, James A . Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet. 1981; 2(8236):1-4. DOI: 10.1016/s0140-6736(81)90249-x. View

11.

Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L . A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns. 2007; 68(1):10-5. DOI: 10.1016/j.pec.2007.05.003. View

12.

Abell S, Boyle J, de Courten B, Knight M, Ranasinha S, Regan J . Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic control. Med J Aust. 2016; 205(4):162-7. DOI: 10.5694/mja16.00443. View

13.

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C . Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022; 4(3):e158-e168. DOI: 10.1016/S2589-7500(21)00271-5. View

14.

Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

15.

Marren S, Hammersley S, McDonald T, Shields B, Knight B, Hill A . Persistent C-peptide is associated with reduced hypoglycaemia but not HbA in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabet Med. 2019; 36(9):1092-1099. PMC: 6790586. DOI: 10.1111/dme.13960. View

16.

Bronstein J, Lawrence R . Two types of diabetes mellitus, with and without available plasma insulin. Br Med J. 1951; 1(4709):732-4. PMC: 2068648. DOI: 10.1136/bmj.1.4709.732. View

17.

Roy T, Lloyd C . Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012; 142 Suppl:S8-21. DOI: 10.1016/S0165-0327(12)70004-6. View

18.

Thomas N, Lynam A, Hill A, Weedon M, Shields B, Oram R . Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019; 62(7):1167-1172. PMC: 6559997. DOI: 10.1007/s00125-019-4863-8. View

19.

Carr A, Inshaw J, Flaxman C, Leete P, Wyatt R, Russell L . Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration. Diabetes. 2022; 71(7):1591-1596. PMC: 9233242. DOI: 10.2337/db22-0097. View

20.

Buckingham B, Cheng P, Beck R, Kollman C, Ruedy K, Weinzimer S . CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia. 2015; 58(6):1167-74. PMC: 4416994. DOI: 10.1007/s00125-015-3559-y. View